We are live on ! Find out more
CNST

Constellation Pharmaceuticals, Inc.
CNST

Delisted

CNST was delisted on the 14th of July, 2021.

100 hedge funds and large institutions have $1.8B invested in Constellation Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,733% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 3

1,292% more capital invested

Capital invested by funds: $129M → $1.8B (+$1.67B)

300% more funds holding in top 10

Funds holding in top 10: 312 (+9)

229% more call options, than puts

Call options by funds: $2.65M | Put options by funds: $807K

117% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 12

108% more funds holding

Funds holding: 48100 (+52)

Holders
100
Holders Change
+52
Holders Change %
+108.33%
% of All Funds
1.97%
Holding in Top 10
12
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+300%
% of All Funds
0.24%
New
55
Increased
26
Reduced
12
Closed
3
Calls
$2.65M
Puts
$807K
Net Calls
+$1.84M
Net Calls Change
+$1.84M
Name Holding Trade Value Shares
Change
Change in
Stake
PS
1
Peter Svennilson
$283M
ACA
2
Avoro Capital Advisors
New York
$172M +$105M +3,650,000 New
TG
3
TRV GP
Massachusetts
$143M
BCLSI
4
Bain Capital Life Sciences Investors
Massachusetts
$133M +$81.5M +2,823,529 New
VMI
5
VHCP Management III
New York
$119M +$70.7M +2,449,575 +3,674%
CAM
6
Cormorant Asset Management
Massachusetts
$108M +$31.4M +1,086,726 +90%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$91.7M +$56.2M +1,945,628 New
ROTUOC
8
Regents of the University of California
California
$82.3M -$15.9M -550,000 -24%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$74.5M +$12.9M +446,328 +39%
VMI
10
VHCP Management II
New York
$70.7M +$22.3M +773,954 +107%
CC
11
Casdin Capital
New York
$57.1M -$8.99M -311,226 -20%
GPP
12
Great Point Partners
Connecticut
$53.5M +$32.8M +1,135,122 New
BlackRock
13
BlackRock
New York
$51.2M +$6.93M +240,129 +28%
Vanguard Group
14
Vanguard Group
Pennsylvania
$44.9M +$7.08M +245,231 +35%
GTC
15
Ghost Tree Capital
New York
$27.1M +$16.6M +575,500 New
Millennium Management
16
Millennium Management
New York
$26.8M +$16.4M +568,799 New
DM
17
Deerfield Management
New York
$25.9M +$15.2M +526,400 +2,231%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$23.6M +$14.5M +500,817 New
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$19M +$1.54M +53,350 +15%
State Street
20
State Street
Massachusetts
$12.9M +$612K +21,214 +8%
Franklin Resources
21
Franklin Resources
California
$11.8M +$7.22M +250,000 New
Jennison Associates
22
Jennison Associates
New York
$11.2M +$6.88M +238,429 New
Canada Pension Plan Investment Board
23
Canada Pension Plan Investment Board
Ontario, Canada
$11.1M +$6.41M +222,000 +1,708%
RSCM
24
Rock Springs Capital Management
Maryland
$11M +$6.74M +233,500 New
Geode Capital Management
25
Geode Capital Management
Massachusetts
$10.7M +$3.41M +118,009 +109%

CNST Hedge Fund Activity: Q4 2019 in Review

100 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q4 2019, worth a combined $1.8B — up 1,292% from $129M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new CNST positions and 3 closed out — a net gain of 52 holders — while 26 added to existing stakes and 12 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $105M. The largest seller was Regents of the University of California, cutting an estimated $15.9M.

  • 100 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q4 2019, up from 48 in Q3 2019.
  • Funds reported $1.8B of Constellation Pharmaceuticals, Inc. stock for Q4 2019, up 1,292% quarter-over-quarter.
  • 55 funds opened new Constellation Pharmaceuticals, Inc. positions in Q4 2019 and 3 closed out, a net change of +52 holders.
  • The largest Constellation Pharmaceuticals, Inc. buyer in Q4 2019 was Avoro Capital Advisors, an estimated $105M added.
  • The largest Constellation Pharmaceuticals, Inc. seller in Q4 2019 was Regents of the University of California, an estimated $15.9M sold.

Based on aggregated 13F filings for Q4 2019.